Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00161642 · ClinicalTrials.gov registry record · Phase 1
Study Evaluating CMD-193 in Advanced Malignant Solid Tumors
A Phase 1 study of Neoplasms, sponsored by Wyeth is now a wholly owned subsidiary of Pfizer.
- Completed
- Registry status
- Phase 1
- Development phase
- 54
- Enrollment target
- 3
- Study locations
NCT00161642: Completed Phase 1 study of Neoplasms, sponsored by Wyeth is now a wholly owned subsidiary of Pfizer.
NCT00161642 is a Phase 1 study of Neoplasms that has completed, run by Wyeth is now a wholly owned subsidiary of Pfizer. The registered enrollment target is 54 participants, below the 1,621-participant average among 158 other Neoplasms trials with a reported enrollment target (97% lower). The trial reports 3 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00161642, a Phase 1 study of Neoplasms, has completed, sponsored by Wyeth is now a wholly owned subsidiary of Pfizer.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 54 participants
- Enrollment target
- 3
- Study locations
Study Summary
The purpose of this study is to determine the safety, tolerability and maximum tolerated dose of CMD-193. Preliminary information about how a person's body processes CMD-193 and how CMD-193 affects tumors will also be collected.
Conditions Studied
Interventions
- DRUG CMD-193
Study Locations (3)
New Hampshire
- - Lebanon
Pennsylvania
- - Philadelphia
Tennessee
- - Nashville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 54 participants |
| Start Date | 2004-11 |
| Est. Completion | 2007-07 |
| Phase | Phase 1 |
What the finished NCT00161642 record still lists
NCT00161642 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 54 participants, a relatively small participant target, below the 1,621-participant average among 158 other Neoplasms trials with a reported enrollment target (97% lower).
The record links to 1 condition, with Neoplasms appearing as the primary indexed condition, and to 1 intervention - of which CMD-193 is the first listed.
NCT00161642 reports a single indexed study location in New Hampshire, Pennsylvania, Tennessee.
Frequently Asked Questions
What is clinical trial NCT00161642 about?
NCT00161642 is a clinical study titled "Study Evaluating CMD-193 in Advanced Malignant Solid Tumors". The purpose of this study is to determine the safety, tolerability and maximum tolerated dose of CMD-193. Preliminary information about how a person's body processes CMD-193 and how CMD-193 affects tumors will also be collected.
What is the current status of trial NCT00161642?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 54 participants. The study started on 2004-11. Estimated completion is 2007-07.
What conditions does trial NCT00161642 study?
This clinical trial studies the following conditions: Neoplasms.
What interventions are being tested in trial NCT00161642?
The interventions under investigation include: CMD-193 (DRUG).
Who is sponsoring clinical trial NCT00161642?
This trial is sponsored by Wyeth is now a wholly owned subsidiary of Pfizer, which has 167 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00161642 being conducted?
This trial has 3 study locations across New Hampshire, Pennsylvania, Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Neoplasms
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00161642's enrollment target sits among peer trials
54 102nd of 158 higher than 57 of 158 other Neoplasms trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Neoplasms trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK) and Preliminary Clinical Activity of RO7673396 in Participants With Advanced Solid Tumors Harboring Rat Sarcoma Viral Oncogene Homolog (RAS) Mutation(s)
RECRUITING · Phase 1
-
A Study of GSK5764227 in Participants With. Advanced Solid Tumors (EMBOLD PanTumor-101)
RECRUITING · Phase 1
-
Adoptive Cell Therapy Long-term Follow-up (LTFU) Study
RECRUITING · Phase 1
-
Two Part Study of Nenocorilant Combined With Nivolumab in Patients With Advanced Solid Malignancies
RECRUITING · Phase 1
-
EMB-01 in Patients With Advanced/Metastatic Gastrointestinal Cancers
RECRUITING · Phase 1
-
Open-Label Study of Pocenbrodib Alone and in Combination With Abiraterone Acetate, Olaparib, or 177Lu-PSMA-617
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01269853 · 54 participants · Phase 1
Repeated Super-selective Intraarterial Cerebral Infusion of Bevacizumab (Avastin) for Treatment of Relapsed GBM and AA
- NCT02390752 · 54 participants · Phase 1
Phase I Trial of TURALIO(R) (Pexidartinib, PLX3397) in Children and Young Adults With Refractory Leukemias and Refractory Solid Tumors Including Neurofibromatosis Type 1 (NF1) Associated Plexiform Neurofibromas (PN) and Tenosynovial Giant Cell Tumor ...
- NCT02991248 · 54 participants · NA
Improve Dynamic Lateral Balance of Humans With SCI
- NCT02993900 · 54 participants · NA
Image-Guided Gynecologic Brachytherapy
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia